Amgen Inc. (AMGN) vs Eli Lilly and Company (LLY)
Amgen Inc. and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $219.1B — 5.1× the size. Amgen Inc. trades at the lower P/E: 25.6× against 39.7×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 9.10%. Eli Lilly and Company has the higher net margin (33.5% vs 23.0%) and the higher return on invested capital (26.3% vs 13.0%). Both pay a dividend; Amgen Inc. yields more (3.16% vs 0.72%). Across the 23 metrics below, Eli Lilly and Company leads on 12 and Amgen Inc. on 11.
Valuation
Profitability
| Metric | AMGN | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.52% | 83.40% | 72.77% |
| Operating margin | 29.99% | 42.22% | 18.90% |
| Net margin | 22.95% | 33.53% | 8.27% |
| Free cash flow margin | 26.71% | 22.83% | 17.25% |
| Return on equity | 91.47% | 102.29% | 6.97% |
| Return on assets | 9.53% | 21.97% | 2.76% |
| Return on invested capital | 12.98% | 26.33% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack